Deborah Jacoby
Family · Phoenix, AZNPI 1255515847
Payments from drug & device makers
Across 341 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Corcept Therapeutics$856
- Lilly USA, LLC$796
- AbbVie$518
- Amgen$482
- Dexcom, Inc.$423
- plus $3K from 32 others
What the payments were for
- Consulting fees$5958%
- Food & beverage$6,42892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $1,010 |
| Corcept Therapeutics | 27 | $856 |
| Lilly USA, LLC | 43 | $796 |
| AbbVie | 24 | $518 |
| Amgen(2 entities) | 29 | $482 |
| Dexcom, Inc. | 48 | $423 |
| Insulet Corporation | 20 | $392 |
| Novo Nordisk | 21 | $384 |
| Sanofi-aventis U.S. LLC | 20 | $332 |
| Boehringer Ingelheim | 12 | $270 |
| BETA Bionics, Inc. | 8 | $153 |
| Abbott | 7 | $146 |
| Tandem Diabetes Care, Inc. | 7 | $137 |
| Medtronic | 7 | $128 |
| Recordati_rare_diseases_inc. | 5 | $103 |
| Mannkind Corporation | 5 | $101 |
| Radius Health, Inc. | 4 | $97 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| BD | 1 | $63 |
| Sequel Med Tech, LLC | 1 | $57 |
| Ascensia Diabetes Care US Inc. | 3 | $56 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| Ascendis Pharma Endocrinology Inc | 2 | $48 |
| Zealand Pharma US, Inc. | 2 | $44 |
| RGH Enterprises LLC | 2 | $36 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| IBSA Pharma Inc. | 2 | $30 |
| Embecta Corp. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Cequr Corporation | 1 | $19 |
| Alvogen Inc | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| Bayer | 1 | $18 |
| Intuity Medical Inc | 1 | $17 |
| GRT US Holding, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$424
How this compares
$7,023 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 209 | $309,704 |
| OzempicSemaglutide | 135 | $261,388 |
| TrulicityDulaglutide | 103 | $183,128 |
| JardianceEmpagliflozin | 68 | $100,846 |
| FarxigaDapagliflozin Propanediol | 49 | $70,728 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $44,566 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $34,658 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $22,284 |
| RybelsusSemaglutide | 15 | $20,949 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $17,917 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $17,796 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $17,631 |
| InvokanaCanagliflozin | 11 | $17,485 |
| VascepaIcosapent Ethyl | 22 | $15,443 |
| SynthroidLevothyroxine Sodium | 128 | $15,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $796 | $505,374367 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $384 | $287,028161 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $270 | $124,88494 claims |
| AstraZenecaFarxiga | $1,010 | $70,72849 claims |
| AbbVieSynthroid | $518 | $15,006128 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $55 | $3,592351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.